AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.
Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders.
Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Country | United States |
IPO Date | Jul 27, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 4 |
CEO | Cary John Claiborne MBA |
Contact Details
Address: 1180 Seminole Trail Charlottesville, Virginia United States | |
Website | https://www.adialpharma.com |
Stock Details
Ticker Symbol | ADIL |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001513525 |
CUSIP Number | 00688A106 |
ISIN Number | US00688A2050 |
Employer ID | 80-0667150 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Cary John Claiborne MBA | Chief Executive Officer, President & Director |
John R. Martin J.D. | Chief Legal Officer |
Joseph A. M. Truluck M.B.A., MBA | Chief Financial Officer, Treasurer & Secretary |
Andrew Taubman | Vice President of Corporate Development |
Catherine Fratila | Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 31, 2024 | 424B3 | Filing |
Dec 20, 2024 | S-1 | Filing |
Dec 18, 2024 | 8-K | Current Report |
Dec 12, 2024 | S-8 | Filing |
Dec 06, 2024 | 8-K | Current Report |
Dec 05, 2024 | 4 | Filing |
Nov 18, 2024 | 8-K | Current Report |
Nov 18, 2024 | 4 | Filing |
Nov 18, 2024 | 3 | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |